Phase I data from Avacta’s lead pre|CISION asset, faridoxorubicin (formerly FAP-Dox, AVA6000) continues to mature, with presentation of full Phase Ia dose escalation data upcoming at the European Society of Medical Oncology (ESMO) 2025 meeting. Further data from salivary gland cancer (SGC) patients enrolled in the Phase Ia/Ib dose escalation and expansion cohorts are expected by year-end, with similar data in TNBC (triple negative breast cancer) following in H126. These data, along with additional pre|CISION platform and pipeline insights that may be revealed in the October pipeline update, could grow partnership interest. AVA6103 (FAP-EXd), Avacta’s second pre|CISION asset and the first to incorporate proprietary sustained release IP, remains on track to begin Phase I in early-2026, with initial data by end-2026. Our Avacta valuation is £457m ($571m), equivalent to 111p/share.
